Bench-Scale Characterization of Cleaning Process Design Space for Biopharmaceuticals - A method to evaluate the relative cleanability of new products. - BioPharm International

ADVERTISEMENT

Bench-Scale Characterization of Cleaning Process Design Space for Biopharmaceuticals
A method to evaluate the relative cleanability of new products.


BioPharm International
Volume 22, Issue 3

Interaction Plots and Surface Response Profiles


Figure 5. Interaction profiles for cross interaction between temperature and concentration of CIP-100 cleaning solution. The intersecting profiles show that these two operating parameters are strongly coupled.
The interaction plots offer a graphical view of any prospective interaction among the various factors. Any evidence of interaction between effects is depicted as nonparallel lines in the interaction plots. Figure 5 shows that the impact of CIP-100 concentration varies depending on the temperature of the cleaning fluid. At high temperatures, a high CIP-100 concentration shortens the cleaning time, whereas at low temperatures, improved cleaning is achieved at lower CIP-100 concentrations. Such interaction profiles as well as the process response surface may be product specific and should be established for each product during the development of the cleaning cycle.

Two-Parameter Design Space


Figure 6. Representation of the design space constructed using two critical operating parameters (temperature and concentration) and the third performance parameter (observed cleaning time)
Figure 6 shows contour plots for cleaning time dependence on temperature and concentration for each of the four products. The plots depict the two-dimensional design space constructed for the cleaning process for all four products. The plots exhibit the effects of cross-interactions between temperature and cleaning agent concentration on the cleaning time as measured through the bench-scale cleaning model.

Based on these contour plots, it can be concluded that there are certain product-specific and general behaviors in the response profiles of cleaning process. All of four products exhibited longer cleaning times at high temperature water conditions, and at low temperature–high CIP-100 concentration conditions. Improved soilant removal is achieved at low temperature–low CIP-100 and high temperature–high CIP-100 values. At ambient temperatures, the cleaning time progressively increases with increase in CIP-100 concentration. The trend is reversed for temperatures ≥70C. Although these general trends are common to the four products, the magnitude of the change, and the specific temperature and concentration values at which the change occurs, are unique to each product. Among the four products, product A is the most difficult to clean (H is least) under the conditions of high temperature and high concentration. Product H, however, becomes the most difficult to clean product in ambient temperature water (0% CIP-100).

These small-scale studies form the foundation for cleaning process characterization work and offer great value in resource savings with respect to both material and time. However, as described earlier in the article, certain elements of the cleaning process could be scale- and equipment-specific. These may include, but are not limited to, equipment shape, location in the bath, spray ball coverage, level of agitation, and fluid flow dynamics. Bridging studies can be conducted to derive the appropriate scaling factors needed to convert small-scale cleaning times to large-scale. The scaling factors would be specific to the equipment, the cleaning bath, and large-scale conditions. Historical monitoring data from the cleaning validation and operation runs also can offer useful information regarding worst-case conditions and suggestions for appropriate parameters for design space characterization.

CONCLUSIONS

A bench-scale model has been developed and used to perform cleanability assessments of protein drug products. The method evaluates the cleaning time of protein soilants deposited on stainless steel coupons and cleaned under simulated large-scale conditions. The model can successfully estimate the relative cleanability of drug products and support a worst-case–based cleaning validation approach.

The model was also used to characterize the effect of varying the operating parameters over a broad process design space on process performance. Statistical analysis using leverage plots show that temperature and concentration of the cleaning solution are critical process parameters, the cross-interaction term being most significant. Self-interaction plot analysis also demonstrates the strong coupling between these two parameters and the product-specific nature of the coupling. Cleanability trends are significantly different for the four products when the temperature and chemical conditions are altered. The findings offer key insights in the significance of various process parameters and the interplay among them that can be useful for both cycle development and optimization.

ACKNOWLEDGMENTS

The authors are thankful to Abe Germansderfer (Corporate Validation, Amgen), Erwin Freund, Anurag S. Rathore, and Ed Walls (Process Development, Amgen) for their critical review and valuable suggestions toward this work.

Nitin Rathore is a senior scientist, Cylia Chen is an associate scientist, and Wenchang Ji is a principal scientist, all in drug product and device development at Amgen, Inc., Thousand Oaks, CA, 805.313.6393,
Wei Qi is a PhD candidate at the department of chemical engineering at the University of Virginia, Charlottesville, VA.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here